Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, and survivorship in patients with rectal cancer. This portion of the guidelines focuses on the management of localized disease, which involves careful patient selection for curative-intent treatment options that sequence multimodality therapy usually comprised of chemotherapy, radiation, and surgical resection.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Rectal Cancer are not printed in this issue of JNCCN but can be accessed online at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Rectal Cancer Panel

At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Rectal Cancer Panel members can be found on page 901. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)

These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

NCCN Rectal Cancer Panel Members

*Al B. Benson III, MD/Chair†

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

*Alan P. Venook, MD/Vice-Chair†‡

UCSF Helen Diller Family Comprehensive Cancer Center

Mahmoud M. Al-Hawary, MDф

University of Michigan Rogel Cancer Center

Lynette Cederquist, MDÞ

UC San Diego Moores Cancer Center

Yi-Jen Chen, MD, PhD§

City of Hope Comprehensive Cancer Center

Kristen K. Ciombor, MD†

Vanderbilt-Ingram Cancer Center

Stacey Cohen, MD†

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Harry S. Cooper, MD≠

Fox Chase Cancer Center

Dustin Deming, MD†

University of Wisconsin Carbone Cancer Center

Paul F. Engstrom, MD†

Fox Chase Cancer Center

Jean L. Grem, MD†

Fred & Pamela Buffett Cancer Center

Axel Grothey, MD†

Mayo Clinic Cancer Center

Howard S. Hochster, MD†

Yale Cancer Center/Smilow Cancer Hospital

Sarah Hoffe, MD§

Moffitt Cancer Center

Steven Hunt, MD¶

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Ahmed Kamel, MDф

University of Alabama at Birmingham Comprehensive Cancer Center

Natalie Kirilcuk, MD¶

Stanford Cancer Institute

Smitha Krishnamurthi, MD†Þ

Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Wells A. Messersmith, MD†

University of Colorado Cancer Center

Jeffrey Meyerhardt, MD, MPH†

Dana-Farber Cancer Institute

Mary F. Mulcahy, MD‡†

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

James D. Murphy, MD, MS§

UC San Diego Moores Cancer Center

Steven Nurkin, MD, MS¶

Roswell Park Comprehensive Cancer Center

Leonard Saltz, MD†‡Þ

Memorial Sloan Kettering Cancer Center

Sunil Sharma, MD†

Huntsman Cancer Institute at the University of Utah

David Shibata, MD¶

St. Jude Children's Research Hospital/The University of Tennessee Health Science Center

John M. Skibber, MD¶

The University of Texas MD Anderson Cancer Center

Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSEф

Memorial Sloan Kettering Cancer Center

Elena M. Stoffel, MD, MPH¤

University of Michigan Rogel Cancer Center

Eden Stotsky-Himelfarb, BSN, RN¥

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Christopher G. Willett, MD§

Duke Cancer Institute

Evan Wuthrick, MD§

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

NCCN Staff: Deborah A. Freedman-Cass, PhD; Kristina M. Gregory, RN, MSN, OCN; and Lisa Gurski, PhD

*Discussion Section Writing Committee

Specialties: †Medical Oncology; §Radiotherapy/Radiation Oncology; ¶Surgery/Surgical Oncology; ≠Pathology; ‡Hematology/Hematology Oncology; ÞInternal Medicine; фDiagnostic/Interventional Radiology; ¤Gastroenterology; ¥Patient Advocate

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:730.

  • 2.

    Cheng L, Eng C, Nieman LZ. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573580.

    • Search Google Scholar
    • Export Citation
  • 3.

    Henley SJ, Singh SD, King J. Invasive cancer incidence and survival—United States, 2011. MMWR Morb Mortal Wkly Rep 2015;64:237242.

  • 4.

    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212236.

    • Search Google Scholar
    • Export Citation
  • 5.

    Bailey CE, Hu CY, You YN. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015;150:1722.

    • Search Google Scholar
    • Export Citation
  • 6.

    Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:10141020.

  • 7.

    Rajput A, Bullard Dunn K. Surgical management of rectal cancer. Semin Oncol 2007;34:241249.

  • 8.

    Weiser MR, Landmann RG, Wong WD. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum 2005;48:11691175.

  • 9.

    Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136147.

  • 10.

    Morino M, Risio M, Bach S. Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc 2015;29:755773.

    • Search Google Scholar
    • Export Citation
  • 11.

    Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am 2002;31:827839.

    • Search Google Scholar
    • Export Citation
  • 12.

    Zhang G, Cai YZ, Xu GH. Diagnostic accuracy of MRI for assessment of T category and circumferential resection margin involvement in patients with rectal cancer: a meta-analysis. Dis Colon Rectum 2016;59:789799.

    • Search Google Scholar
    • Export Citation
  • 13.

    Balyasnikova S, Brown G. Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options Oncol 2016;17:32.

  • 14.

    Battersby NJ, How P, Moran B. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016;263:751760.

    • Search Google Scholar
    • Export Citation
  • 15.

    Beets-Tan RG, Beets GL. Rectal cancer: review with emphasis on MR imaging. Radiology 2004;232:335346.

  • 16.

    Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: the current role of MRI. Eur Radiol 2007;17:379389.

  • 17.

    Lahaye MJ, Engelen SM, Nelemans PJ. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 2005;26:259268.

    • Search Google Scholar
    • Export Citation
  • 18.

    Xie H, Zhou X, Zhuo Z. Effectiveness of MRI for the assessment of mesorectal fascia involvement in patients with rectal cancer: a systematic review and meta-analysis. Dig Surg 2014;31:123134.

    • Search Google Scholar
    • Export Citation
  • 19.

    Taylor FG, Quirke P, Heald RJ. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014;32:3443.

    • Search Google Scholar
    • Export Citation
  • 20.

    Faletti R, Gatti M, Arezzo A. Preoperative staging of rectal cancer using magnetic resonance imaging: comparison with pathological staging. Minerva Chir 2018;73:1319.

    • Search Google Scholar
    • Export Citation
  • 21.

    Beets-Tan RG, Lambregts DM, Maas M. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2018;28:14651475.

    • Search Google Scholar
    • Export Citation
  • 22.

    Bipat S, Glas AS, Slors FJM. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology 2004;232:773783.

    • Search Google Scholar
    • Export Citation
  • 23.

    Wolberink SV, Beets-Tan RG, de Haas-Kock DF. Conventional CT for the prediction of an involved circumferential resection margin in primary rectal cancer. Dig Dis 2007;25:8085.

    • Search Google Scholar
    • Export Citation
  • 24.

    Ashraf S, Hompes R, Slater A. A critical appraisal of endorectal ultrasound and transanal endoscopic microsurgery and decision-making in early rectal cancer. Colorectal Dis 2012;14:821826.

    • Search Google Scholar
    • Export Citation
  • 25.

    Choi DJ, Kwak JM, Kim J. Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. J Surg Oncol 2010;102:588592.

    • Search Google Scholar
    • Export Citation
  • 26.

    Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM. Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol 2010;17:20452050.

    • Search Google Scholar
    • Export Citation
  • 27.

    Qiu M, Hu J, Yang D. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget 2015;6:3865838666.

  • 28.

    Hayashi M, Inoue Y, Komeda K. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010;10:27.

    • Search Google Scholar
    • Export Citation
  • 29.

    Muratore A, Zorzi D, Bouzari H. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766770.

    • Search Google Scholar
    • Export Citation
  • 30.

    de Jong EA, Ten Berge JC, Dwarkasing RS. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis. Surgery 2016;159:688699.

    • Search Google Scholar
    • Export Citation
  • 31.

    Dickman R, Kundel Y, Levy-Drummer R. Restaging locally advanced rectal cancer by different imaging modalities after preoperative chemoradiation: a comparative study. Radiat Oncol 2013;8:278.

    • Search Google Scholar
    • Export Citation
  • 32.

    Guillem JG, Ruby JA, Leibold T. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg 2013;258:289295.

    • Search Google Scholar
    • Export Citation
  • 33.

    Hanly AM, Ryan EM, Rogers AC. Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) therapy. Ann Surg 2014;259:723727.

    • Search Google Scholar
    • Export Citation
  • 34.

    Kuo LJ, Chiou JF, Tai CJ. Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? Int J Colorectal Dis 2012;27:613621.

    • Search Google Scholar
    • Export Citation
  • 35.

    Memon S, Lynch AC, Bressel M. Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis 2015;17:748761.

    • Search Google Scholar
    • Export Citation
  • 36.

    Ryan JE, Warrier SK, Lynch AC, Heriot AG. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis 2015;17:849861.

    • Search Google Scholar
    • Export Citation
  • 37.

    van der Paardt MP, Zagers MB, Beets-Tan RG. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 2013;269:101112.

    • Search Google Scholar
    • Export Citation
  • 38.

    Zhao RS, Wang H, Zhou ZY. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. Dis Colon Rectum 2014;57:388395.

    • Search Google Scholar
    • Export Citation
  • 39.

    Park HJ, Jang JK, Park SH. Restaging abdominopelvic computed tomography before surgery after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. JAMA Oncol 2018;4:259262.

    • Search Google Scholar
    • Export Citation
  • 40.

    Hotker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum 2014;57:790799.

    • Search Google Scholar
    • Export Citation
  • 41.

    Joye I, Deroose CM, Vandecaveye V, Haustermans K. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol 2014;113:158165.

    • Search Google Scholar
    • Export Citation
  • 42.

    Lambregts DM, Rao SX, Sassen S. MRI and diffusion-weighted MRI molumetry for identification of complete tumor responders after preoperative chemoradiotherapy in patients with rectal cancer: a bi-institutional validation study. Ann Surg 2015;262:10341039.

    • Search Google Scholar
    • Export Citation
  • 43.

    Memon S, Lynch AC, Akhurst T. Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. Ann Surg Oncol 2014;21:35983607.

    • Search Google Scholar
    • Export Citation
  • 44.

    Guillem JG, Cohen AM. Current issues in colorectal cancer surgery. Semin Oncol 1999;26:505513.

  • 45.

    Lindsetmo RO, Joh YG, Delaney CP. Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. World J Gastroenterol 2008;14:32813289.

    • Search Google Scholar
    • Export Citation
  • 46.

    Willett CG, Compton CC, Shellito PC, Efird JT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer 1994;73:27162720.

    • Search Google Scholar
    • Export Citation
  • 47.

    Clancy C, Burke JP, Albert MR. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. Dis Colon Rectum 2015;58:254261.

    • Search Google Scholar
    • Export Citation
  • 48.

    Chen Y, Guo R, Xie J. Laparoscopy combined with transanal endoscopic microsurgery for rectal cancer: a prospective, single-blinded, randomized clinical trial. Surg Laparosc Endosc Percutan Tech 2015;25:399402.

    • Search Google Scholar
    • Export Citation
  • 49.

    Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002;45:200206.

    • Search Google Scholar
    • Export Citation
  • 50.

    Yamamoto S, Watanabe M, Hasegawa H. The risk of lymph node metastasis in T1 colorectal carcinoma. Hepatogastroenterology 2004;51:9981000.

  • 51.

    You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 2007;245:726733.

    • Search Google Scholar
    • Export Citation
  • 52.

    Garcia-Aguilar J, Renfro LA, Chow OS. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015;16:15371546.

    • Search Google Scholar
    • Export Citation
  • 53.

    Shaikh I, Askari A, Ouru S. Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2015;30:1929.

    • Search Google Scholar
    • Export Citation
  • 54.

    Landmann RG, Wong WD, Hoepfl J. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum 2007;50:15201525.

    • Search Google Scholar
    • Export Citation
  • 55.

    Kidane B, Chadi SA, Kanters S. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum 2015;58:122140.

    • Search Google Scholar
    • Export Citation
  • 56.

    Nash GM, Weiser MR, Guillem JG. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009;52:577582.

  • 57.

    Stitzenberg KB, Sanoff HK, Penn DC. Practice patterns and long-term survival for early-stage rectal cancer. J Clin Oncol 2013;31:42764282.

  • 58.

    Sajid MS, Farag S, Leung P. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis 2014;16:214.

    • Search Google Scholar
    • Export Citation
  • 59.

    Lu JY, Lin GL, Qiu HZ. Comparison of transanal endoscopic microsurgery and total mesorectal excision in the treatment of T1 rectal cancer: a meta-analysis. PLoS One 2015;10:e0141427.

    • Search Google Scholar
    • Export Citation
  • 60.

    Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 1982;69:613616.

  • 61.

    Steup WH, Moriya Y, van de Velde CJ. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer 2002;38:911918.

    • Search Google Scholar
    • Export Citation
  • 62.

    Schlag PM. Surgical sphincter preservation in rectal cancer. Oncologist 1996;1:288292.

  • 63.

    Marr R, Birbeck K, Garvican J. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005;242:7482.

    • Search Google Scholar
    • Export Citation
  • 64.

    Russell MM, Ganz PA, Lopa S. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. Ann Surg 2015;261:144148.

    • Search Google Scholar
    • Export Citation
  • 65.

    Huang A, Zhao H, Ling T. Oncological superiority of extralevator abdominoperineal resection over conventional abdominoperineal resection: a meta-analysis. Int J Colorectal Dis 2014;29:321327.

    • Search Google Scholar
    • Export Citation
  • 66.

    Negoi I, Hostiuc S, Paun S. Extralevator vs conventional abdominoperineal resection for rectal cancer-a systematic review and meta-analysis. Am J Surg 2016;212:511526.

    • Search Google Scholar
    • Export Citation
  • 67.

    Nagtegaal ID, van de Velde CJ, van der Worp E. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002;20:17291734.

    • Search Google Scholar
    • Export Citation
  • 68.

    Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol 2007;60:849855.

    • Search Google Scholar
    • Export Citation
  • 69.

    Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemoradiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006;8:800807.

    • Search Google Scholar
    • Export Citation
  • 70.

    Nagtegaal ID, Marijnen CA, Kranenbarg EK. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350357.

    • Search Google Scholar
    • Export Citation
  • 71.

    Wibe A, Rendedal PR, Svensson E. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89:327334.

    • Search Google Scholar
    • Export Citation
  • 72.

    den Dulk M, Putter H, Collette L. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer 2009;45:11751183.

    • Search Google Scholar
    • Export Citation
  • 73.

    Pahlman L, Bohe M, Cedermark B. The Swedish rectal cancer registry. Br J Surg 2007;94:12851292.

  • 74.

    Digennaro R, Tondo M, Cuccia F. Coloanal anastomosis or abdominoperineal resection for very low rectal cancer: what will benefit, the surgeon's pride or the patient's quality of life? Int J Colorectal Dis 2013;28:949957.

    • Search Google Scholar
    • Export Citation
  • 75.

    Pachler J, Wille-Jorgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 2012;12:CD004323.

    • Search Google Scholar
    • Export Citation
  • 76.

    Bonjer HJ, Deijen CL, Abis GA. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 2015;372:13241332.

  • 77.

    Jeong SY, Park JW, Nam BH. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014;15:767774.

    • Search Google Scholar
    • Export Citation
  • 78.

    Fleshman J, Branda M, Sargent DJ. Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA 2015;314:13461355.

    • Search Google Scholar
    • Export Citation
  • 79.

    Stevenson AR, Solomon MJ, Lumley JW. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA 2015;314:13561363.

    • Search Google Scholar
    • Export Citation
  • 80.

    Lujan J, Valero G, Biondo S. Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4,970 patients. Surg Endosc 2013;27:295302.

    • Search Google Scholar
    • Export Citation
  • 81.

    van der Pas MH, Haglind E, Cuesta MA. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013;14:210218.

    • Search Google Scholar
    • Export Citation
  • 82.

    Jayne DG, Guillou PJ, Thorpe H. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007;25:30613068.

    • Search Google Scholar
    • Export Citation
  • 83.

    Jayne DG, Thorpe HC, Copeland J. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 2010;97:16381645.

    • Search Google Scholar
    • Export Citation
  • 84.

    Kang SB, Park JW, Jeong SY. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010;11:637645.

    • Search Google Scholar
    • Export Citation
  • 85.

    Wagman LD. Laparoscopic and open surgery for colorectal cancer: reaching equipoise? J Clin Oncol 2007;25:29962998.

  • 86.

    Nussbaum DP, Speicher PJ, Ganapathi AM. Laparoscopic versus open low anterior resection for rectal cancer: results from the National Cancer Data Base. J Gastrointest Surg 2014;19:124131.

    • Search Google Scholar
    • Export Citation
  • 87.

    Araujo SE, da Silva eSousa AH Jr, de Campos FG. Conventional approach x laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial. Rev Hosp Clin Fac Med Sao Paulo 2003;58:133140.

    • Search Google Scholar
    • Export Citation
  • 88.

    Gopall J, Shen XF, Cheng Y. Current status of laparoscopic total mesorectal excision. Am J Surg 2012;203:230241.

  • 89.

    Kuhry E, Schwenk WF, Gaupset R. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008:CD003432.

  • 90.

    Lee JK, Delaney CP, Lipman JM. Current state of the art in laparoscopic colorectal surgery for cancer: update on the multi-centric international trials. Ann Surg Innov Res 2012;6:5.

    • Search Google Scholar
    • Export Citation
  • 91.

    Trastulli S, Cirocchi R, Listorti C. Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Colorectal Dis 2012;14:e277296.

    • Search Google Scholar
    • Export Citation
  • 92.

    Xiong B, Ma L, Zhang C. Laparoscopic versus open total mesorectal excision for middle and low rectal cancer: a meta-analysis of results of randomized controlled trials. J Laparoendosc Adv Surg Tech A 2012;22:674684.

    • Search Google Scholar
    • Export Citation
  • 93.

    Ahmad NZ, Racheva G, Elmusharaf H. A systematic review and meta-analysis of randomized and non-randomized studies comparing laparoscopic and open abdominoperineal resection for rectal cancer. Colorectal Dis 2013;15:269277.

    • Search Google Scholar
    • Export Citation
  • 94.

    Arezzo A, Passera R, Scozzari G. Laparoscopy for rectal cancer reduces short-term mortality and morbidity: results of a systematic review and meta-analysis. Surg Endosc 2013;27:14851502.

    • Search Google Scholar
    • Export Citation
  • 95.

    Jiang JB, Jiang K, Dai Y. Laparoscopic versus open surgery for mid-low rectal cancer: a systematic review and meta-analysis on short- and long-term outcomes. J Gastrointest Surg 2015;19:14971512.

    • Search Google Scholar
    • Export Citation
  • 96.

    Morneau M, Boulanger J, Charlebois P. Laparoscopic versus open surgery for the treatment of colorectal cancer: a literature review and recommendations from the Comite de l'evolution des pratiques en oncologie. Can J Surg 2013;56:297310.

    • Search Google Scholar
    • Export Citation
  • 97.

    Ng SS, Lee JF, Yiu RY. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. Ann Surg 2014;259:139147.

    • Search Google Scholar
    • Export Citation
  • 98.

    Vennix S, Pelzers L, Bouvy N. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev 2014;4:CD005200.

    • Search Google Scholar
    • Export Citation
  • 99.

    Zhang FW, Zhou ZY, Wang HL. Laparoscopic versus open surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 2014;15:99859996.

    • Search Google Scholar
    • Export Citation
  • 100.

    Zhao D, Li Y, Wang S, Huang Z. Laparoscopic versus open surgery for rectal cancer: a meta-analysis of 3-year follow-up outcomes. Int J Colorectal Dis 2016;31:805811.

    • Search Google Scholar
    • Export Citation
  • 101.

    Martinez-Perez A, Carra MC, Brunetti F, de'Angelis N. Pathologic outcomes of laparoscopic vs open mesorectal excision for rectal cancer: a systematic review and meta-analysis. JAMA Surg 2017;152:e165665.

    • Search Google Scholar
    • Export Citation
  • 102.

    Huang YM, Huang YJ, Wei PL. Outcomes of robotic versus laparoscopic surgery for mid and low rectal cancer after neoadjuvant chemoradiation therapy and the effect of learning curve. Medicine (Baltimore) 2017;96:e8171.

    • Search Google Scholar
    • Export Citation
  • 103.

    Jayne D, Pigazzi A, Marshall H. effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 2017;318:15691580.

    • Search Google Scholar
    • Export Citation
  • 104.

    Kim MJ, Park SC, Park JW. Robot-assisted versus laparoscopic surgery for rectal cancer: a phase II open label prospective randomized controlled trial. Ann Surg 2018;267:243251.

    • Search Google Scholar
    • Export Citation
  • 105.

    Li X, Wang T, Yao L. The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer: a meta-analysis and systematic review. Medicine (Baltimore) 2017;96:e7585.

    • Search Google Scholar
    • Export Citation
  • 106.

    Prete FP, Pezzolla A, Prete F. Robotic versus laparoscopic minimally invasive surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Surg 2018;267:10341046.

    • Search Google Scholar
    • Export Citation
  • 107.

    Miskovic D, Foster J, Agha A. Standardization of laparoscopic total mesorectal excision for rectal cancer: a structured international expert consensus. Ann Surg 2015;261:716722.

    • Search Google Scholar
    • Export Citation
  • 108.

    Lai LL, Fuller CD, Kachnic LA, Thomas CR Jr. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol 2006;33:S7074.

    • Search Google Scholar
    • Export Citation
  • 109.

    Peeters KC, van de Velde CJ, Leer JW. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 2005;23:61996206.

    • Search Google Scholar
    • Export Citation
  • 110.

    Rahbari NN, Elbers H, Askoxylakis V. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol 2013;20:41694182.

    • Search Google Scholar
    • Export Citation
  • 111.

    Gunderson LL, Sargent DJ, Tepper JE. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:17851796.

    • Search Google Scholar
    • Export Citation
  • 112.

    Tepper JE, O'Connell M, Niedzwiecki D. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol 2002;20:17441750.

    • Search Google Scholar
    • Export Citation
  • 113.

    Guillem JG, Diaz-Gonzalez JA, Minsky BD. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008;26:368373.

    • Search Google Scholar
    • Export Citation
  • 114.

    Sauer R, Becker H, Hohenberger W. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:17311740.

  • 115.

    Wagman R, Minsky BD, Cohen AM. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998;42:5157.

    • Search Google Scholar
    • Export Citation
  • 116.

    Sauer R, Liersch T, Merkel S. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:19261933.

    • Search Google Scholar
    • Export Citation
  • 117.

    Peng LC, Milsom J, Garrett K. Surveillance, Epidemiology, and End Results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer. Cancer Epidemiol 2014;38:7378.

    • Search Google Scholar
    • Export Citation
  • 118.

    Kachnic LA. Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol 2006;33:S6469.

    • Search Google Scholar
    • Export Citation
  • 119.

    Bujko K, Kepka L, Michalski W, Nowacki MP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 2006;80:412.

    • Search Google Scholar
    • Export Citation
  • 120.

    Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007:CD002102.

    • Search Google Scholar
    • Export Citation
  • 121.

    Madoff RD. Chemoradiotherapy for rectal cancer—when, why, and how? N Engl J Med 2004;351:17901792.

  • 122.

    Gerard JP, Conroy T, Bonnetain F. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:46204625.

    • Search Google Scholar
    • Export Citation
  • 123.

    Bosset JF, Calais G, Mineur L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 2005;23:56205627.

    • Search Google Scholar
    • Export Citation
  • 124.

    Bosset JF, Collette L, Calais G. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:11141123.

  • 125.

    Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009:CD006041.

    • Search Google Scholar
    • Export Citation
  • 126.

    McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012;12:CD008368.

    • Search Google Scholar
    • Export Citation
  • 127.

    De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013:CD006041.

    • Search Google Scholar
    • Export Citation
  • 128.

    Smalley SR, Benedetti JK, Williamson SK. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006;24:35423547.

    • Search Google Scholar
    • Export Citation
  • 129.

    O'Connell MJ, Martenson JA, Wieand HS. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502507.

    • Search Google Scholar
    • Export Citation
  • 130.

    Hofheinz RD, Wenz F, Post S. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579588.

    • Search Google Scholar
    • Export Citation
  • 131.

    O'Connell MJ, Colangelo LH, Beart RW. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:19271934.

    • Search Google Scholar
    • Export Citation
  • 132.

    Allegra CJ, Yothers G, O'Connell MJ. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst 2015;107: pii: djv248.

    • Search Google Scholar
    • Export Citation
  • 133.

    Aschele C, Cionini L, Lonardi S. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:27732780.

    • Search Google Scholar
    • Export Citation
  • 134.

    Gerard JP, Azria D, Gourgou-Bourgade S. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012;30:45584565.

    • Search Google Scholar
    • Export Citation
  • 135.

    Azria D, Doyen J, Jarlier M. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol 2017;28:24362442.

    • Search Google Scholar
    • Export Citation
  • 136.

    Rodel C, Graeven U, Fietkau R. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:979989.

    • Search Google Scholar
    • Export Citation
  • 137.

    Rodel C, Liersch T, Becker H. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679687.

    • Search Google Scholar
    • Export Citation
  • 138.

    Glynne-Jones R. Rectal cancer—the times they are a-changing. Lancet Oncol 2012;13:651653.

  • 139.

    Deng Y, Chi P, Lan P. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol 2016;34:33003307.

    • Search Google Scholar
    • Export Citation
  • 140.

    Feng YR, Zhu Y, Liu LY. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial. Oncotarget 2016;7:2557625584.

    • Search Google Scholar
    • Export Citation
  • 141.

    Dewdney A, Cunningham D, Tabernero J. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30:16201627.

    • Search Google Scholar
    • Export Citation
  • 142.

    Eisterer W, De Vries A, Ofner D. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer—a phase II clinical trial. Anticancer Res 2014;34:67676773.

    • Search Google Scholar
    • Export Citation
  • 143.

    Kripp M, Horisberger K, Mai S. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase II trials. Gastroenterol Res Pract 2015;2015:273489.

    • Search Google Scholar
    • Export Citation
  • 144.

    Helbling D, Bodoky G, Gautschi O. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2013;24:718725.

    • Search Google Scholar
    • Export Citation
  • 145.

    Pinto C, Di Bisceglie M, Di Fabio F. Phase II study of preoperative treatment with external radiotherapy plus panitumumab in low-risk, locally advanced rectal cancer (RaP Study/STAR-03) [published online March 9, 2018]. Oncologist, doi: 10.1634/theoncologist.2017-0484

    • Search Google Scholar
    • Export Citation
  • 146.

    Landry JC, Feng Y, Prabhu RS. Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN Cancer Research Group E3204. Oncologist 2015;20:615616.

    • Search Google Scholar
    • Export Citation
  • 147.

    Chiorean EG, Sanghani S, Schiel MA. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemother Pharmacol 2012;70:2532.

    • Search Google Scholar
    • Export Citation
  • 148.

    Kim SY, Hong YS, Kim DY. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys 2011;81:677683.

    • Search Google Scholar
    • Export Citation
  • 149.

    Spigel DR, Bendell JC, McCleod M. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012;11:4552.

    • Search Google Scholar
    • Export Citation
  • 150.

    Cercek A, Goodman KA, Hajj C. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014;12:513519.

    • Search Google Scholar
    • Export Citation
  • 151.

    Chau I, Brown G, Cunningham D. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668674.

    • Search Google Scholar
    • Export Citation
  • 152.

    Fernandez-Martos C, Pericay C, Aparicio J. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer De Recto 3 study. J Clin Oncol 2010;28:859865.

    • Search Google Scholar
    • Export Citation
  • 153.

    Perez K, Safran H, Sikov W. Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE study. Am J Clin Oncol 2014;40:283287.

    • Search Google Scholar
    • Export Citation
  • 154.

    Marechal R, Vos B, Polus M. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012;23:15251530.

    • Search Google Scholar
    • Export Citation
  • 155.

    Nogue M, Salud A, Vicente P. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011;16:614620.

    • Search Google Scholar
    • Export Citation
  • 156.

    Fernandez-Martos C, Garcia-Albeniz X, Pericay C. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 2015;26:17221728.

    • Search Google Scholar
    • Export Citation
  • 157.

    Schrag D, Weiser MR, Goodman KA. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513518.

    • Search Google Scholar
    • Export Citation
  • 158.

    Hasegawa S, Goto S, Matsumoto T. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Ann Surg Oncol 2017;24:35873595.

    • Search Google Scholar
    • Export Citation
  • 159.

    Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer. J Gastrointest Cancer 2015;46:219236.

    • Search Google Scholar
    • Export Citation
  • 160.

    Gay HA, Barthold HJ, O'Meara E. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012;83:e353362.

    • Search Google Scholar
    • Export Citation
  • 161.

    Francois Y, Nemoz CJ, Baulieux J. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396.

    • Search Google Scholar
    • Export Citation
  • 162.

    Habr-Gama A, Perez RO, Proscurshim I. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008;71:11811188.

    • Search Google Scholar
    • Export Citation
  • 163.

    Moore HG, Gittleman AE, Minsky BD. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279286.

    • Search Google Scholar
    • Export Citation
  • 164.

    Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 2016;263:458464.

    • Search Google Scholar
    • Export Citation
  • 165.

    Sloothaak DA, Geijsen DE, van Leersum NJ. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013;100:933939.

    • Search Google Scholar
    • Export Citation
  • 166.

    Tulchinsky H, Shmueli E, Figer A. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:26612667.

    • Search Google Scholar
    • Export Citation
  • 167.

    Probst CP, Becerra AZ, Aquina CT. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg 2015;221:430440.

    • Search Google Scholar
    • Export Citation
  • 168.

    Huntington CR, Boselli D, Symanowski J. Optimal timing of surgical resection after radiation in locally advanced rectal adenocarcinoma: an analysis of the National Cancer Database. Ann Surg Oncol 2016;23:877887.

    • Search Google Scholar
    • Export Citation
  • 169.

    Sun Z, Adam MA, Kim J. Optimal timing to surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Am Coll Surg 2016;222:367374.

    • Search Google Scholar
    • Export Citation
  • 170.

    Lefevre JH, Mineur L, Kotti S. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016;34:37733780.

    • Search Google Scholar
    • Export Citation
  • 171.

    Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980987.

    • Search Google Scholar
    • Export Citation
  • 172.

    Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23:86978705.

    • Search Google Scholar
    • Export Citation
  • 173.

    Kapiteijn E, Marijnen CA, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638646.

    • Search Google Scholar
    • Export Citation
  • 174.

    Peeters KC, Marijnen CA, Nagtegaal ID. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693701.

    • Search Google Scholar
    • Export Citation
  • 175.

    Siegel R, Burock S, Wernecke KD. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 2009;9:50.

    • Search Google Scholar
    • Export Citation
  • 176.

    Sebag-Montefiore D, Stephens RJ, Steele R. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811820.

    • Search Google Scholar
    • Export Citation
  • 177.

    Stephens RJ, Thompson LC, Quirke P. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010;28:42334239.

    • Search Google Scholar
    • Export Citation
  • 178.

    van Gijn W, Marijnen CA, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575582.

    • Search Google Scholar
    • Export Citation
  • 179.

    Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:12151223.

    • Search Google Scholar
    • Export Citation
  • 180.

    Ngan SY, Burmeister B, Fisher RJ. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30:38273833.

    • Search Google Scholar
    • Export Citation
  • 181.

    Ansari N, Solomon MJ, Fisher RJ. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). Ann Surg 2017;265:882888.

    • Search Google Scholar
    • Export Citation
  • 182.

    McLachlan SA, Fisher RJ, Zalcberg J. The impact on health-related quality of life in the first 12 months: a randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group trial 01.04). Eur J Cancer 2016;55:1526.

    • Search Google Scholar
    • Export Citation
  • 183.

    Latkauskas T, Pauzas H, Gineikiene I. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis 2012;14:294298.

    • Search Google Scholar
    • Export Citation
  • 184.

    Latkauskas T, Pauzas H, Kairevice L. Preoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer: results of a randomized controlled trial. BMC Cancer 2016;16:927.

    • Search Google Scholar
    • Export Citation
  • 185.

    Bujko K, Partycki M, Pietrzak L. Neoadjuvant radiotherapy (5 x 5 Gy): immediate versus delayed surgery. Recent Results Cancer Res 2014;203:171187.

    • Search Google Scholar
    • Export Citation
  • 186.

    Nilsson PJ, van Etten B, Hospers GA. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial. BMC Cancer 2013;13:279.

    • Search Google Scholar
    • Export Citation
  • 187.

    Collette L, Bosset J-F, den Dulk M. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007;25:43794386.

    • Search Google Scholar
    • Export Citation
  • 188.

    Das P, Skibber JM, Rodriguez-Bigas MA. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 2006;29:219224.

    • Search Google Scholar
    • Export Citation
  • 189.

    Das P, Skibber JM, Rodriguez-Bigas MA. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007;109:17501755.

    • Search Google Scholar
    • Export Citation
  • 190.

    Fietkau R, Barten M, Klautke G. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006;49:12841292.

    • Search Google Scholar
    • Export Citation
  • 191.

    Park IJ, You YN, Agarwal A. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012;30:17701776.

    • Search Google Scholar
    • Export Citation
  • 192.

    Silberfein EJ, Kattepogu KM, Hu CY. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol 2010;17:28632869.

    • Search Google Scholar
    • Export Citation
  • 193.

    Smith KD, Tan D, Das P. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 2010;251:261264.

    • Search Google Scholar
    • Export Citation
  • 194.

    Patel UB, Taylor F, Blomqvist L. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29:37533760.

    • Search Google Scholar
    • Export Citation
  • 195.

    Fokas E, Liersch T, Fietkau R. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014;32:15541562.

    • Search Google Scholar
    • Export Citation
  • 196.

    Fokas E, Strobel P, Fietkau R. Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J Natl Cancer Inst 2017;109:djx095.

    • Search Google Scholar
    • Export Citation
  • 197.

    Karagkounis G, Thai L, Mace AG. Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage III rectal cancer [published online February 20, 2018]. Ann Surg, doi: 10.1097/SLA.0000000000002719

    • Search Google Scholar
    • Export Citation
  • 198.

    Janjan NA, Crane C, Feig BW. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001;24:107112.

    • Search Google Scholar
    • Export Citation
  • 199.

    Habr-Gama A, Perez RO, Nadalin W. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711717.

    • Search Google Scholar
    • Export Citation
  • 200.

    Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? Dis Colon Rectum 2008;51:1019.

    • Search Google Scholar
    • Export Citation
  • 201.

    Maas M, Beets-Tan RG, Lambregts DM. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011;29:46334640.

    • Search Google Scholar
    • Export Citation
  • 202.

    Appelt AL, Ploen J, Harling H. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 2015;16:919927.

    • Search Google Scholar
    • Export Citation
  • 203.

    Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88:822828.

    • Search Google Scholar
    • Export Citation
  • 204.

    Li J, Liu H, Yin J. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget 2015;6:4235442361.

    • Search Google Scholar
    • Export Citation
  • 205.

    Renehan AG, Malcomson L, Emsley R. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17:174183.

    • Search Google Scholar
    • Export Citation
  • 206.

    Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017;2:501513.

    • Search Google Scholar
    • Export Citation
  • 207.

    Sammour T, Price BA, Krause KJ, Chang GJ. Nonoperative management or ‘watch and wait’ for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol 2017;24:19041915.

    • Search Google Scholar
    • Export Citation
  • 208.

    Kong JC, Guerra GR, Warrier SK. Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 2017;60:335345.

    • Search Google Scholar
    • Export Citation
  • 209.

    Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012;99:897909.

    • Search Google Scholar
    • Export Citation
  • 210.

    Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum 2016;59:255263.

    • Search Google Scholar
    • Export Citation
  • 211.

    Tranchart H, Lefevre JH, Svrcek M. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? Ann Surg Oncol 2013;20:15511559.

    • Search Google Scholar
    • Export Citation
  • 212.

    Ellis CT, Samuel CA, Stitzenberg KB. National trends in nonoperative management of rectal adenocarcinoma. J Clin Oncol 2016;34:16441651.

  • 213.

    Ellis CT, Dusetzina SB, Sanoff H, Stitzenberg KB. Long-term survival after chemoradiotherapy without surgery for rectal adenocarcinoma: a word of caution. JAMA Oncol 2017;3:123125.

    • Search Google Scholar
    • Export Citation
  • 214.

    Bujko K, Glimelius B, Valentini V. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo) therapy: a meta-analysis of randomized trials comparing surgery +/- a fluoropyrimidine and surgery + a fluoropyrimidine +/- oxaliplatin. Eur J Surg Oncol 2015;41:713723.

    • Search Google Scholar
    • Export Citation
  • 215.

    Wolmark N, Wieand HS, Hyams DM. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R-02. J Natl Cancer Inst 2000;92:388396.

    • Search Google Scholar
    • Export Citation
  • 216.

    Bosset JF, Calais G, Mineur L. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15:184190.

    • Search Google Scholar
    • Export Citation
  • 217.

    Sainato A, Cernusco Luna Nunzia V, Valentini V. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 2014;113:223229.

    • Search Google Scholar
    • Export Citation
  • 218.

    Breugom AJ, van Gijn W, Muller EW. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 2015;26:696701.

    • Search Google Scholar
    • Export Citation
  • 219.

    Benson AB, Catalan P, Meropol NJ. ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/III rectal cancer receiving either pre or postoperative radiation (RT)/FU [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 3526.

    • Search Google Scholar
    • Export Citation
  • 220.

    Hong YS, Nam BH, Kim KP. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014;15:12451253.

    • Search Google Scholar
    • Export Citation
  • 221.

    Garcia-Albeniz X, Gallego R, Hofheinz RD. Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World J Gastroenterol 2014;20:1582015829.

    • Search Google Scholar
    • Export Citation
  • 222.

    Breugom AJ, Swets M, Bosset JF. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:200207.

    • Search Google Scholar
    • Export Citation
  • 223.

    Petersen SH, Harling H, Kirkeby LT. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;3:CD004078.

    • Search Google Scholar
    • Export Citation
  • 224.

    Petrelli F, Coinu A, Lonati V, Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 2015;30:447457.

    • Search Google Scholar
    • Export Citation
  • 225.

    Carvalho C, Glynne-Jones R. Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol 2017;18:e354363.

    • Search Google Scholar
    • Export Citation
  • 226.

    Loree JM, Kennecke HF, Lee-Ying RM. Impact of postoperative adjuvant chemotherapy following long-course chemoradiotherapy in stage II rectal cancer. Am J Clin Oncol 2018;41:643648.

    • Search Google Scholar
    • Export Citation
  • 227.

    Hu X, Li YQ, Li QG. Adjuvant chemotherapy seemed not to have survival benefit in rectal cancer patients with ypTis-2N0 after preoperative radiotherapy and surgery from a population-based propensity score analysis [published online April 19, 2018]. Oncologist, doi: 10.1634/theoncologist.2017-0600

    • Search Google Scholar
    • Export Citation
  • 228.

    Garlipp B, Ptok H, Benedix F. Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database. Langenbecks Arch Surg 2016;401:11791190.

    • Search Google Scholar
    • Export Citation
  • 229.

    Polanco PM, Mokdad AA, Zhu H. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection [published online April 19, 2018]. JAMA Oncol, doi: 10.1001/jamaoncol.2018.0231

    • Search Google Scholar
    • Export Citation
  • 230.

    Shahab D, Gabriel E, Attwood K. Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer 2017;16:300307.

    • Search Google Scholar
    • Export Citation
  • 231.

    Khrizman P, Niland JC, ter Veer A. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 2013;31:3038.

    • Search Google Scholar
    • Export Citation
  • 232.

    Haynes AB, You YN, Hu CY. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 2014;120:11621170.

    • Search Google Scholar
    • Export Citation
  • 233.

    Biagi JJ, Raphael MJ, Mackillop WJ. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011;305:23352342.

    • Search Google Scholar
    • Export Citation
  • 234.

    Des Guetz G, Nicolas P, Perret GY. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46:10491055.

    • Search Google Scholar
    • Export Citation
  • 235.

    Fakih M. Treating rectal cancer: key issues reconsidered. Oncology (Williston Park) 2008;22:14441446.

  • 236.

    Minsky BD, Guillem JG. Multidisciplinary management of resectable rectal cancer. New developments and controversies. Oncology (Williston Park) 2008;22:14301437.

    • Search Google Scholar
    • Export Citation
  • 237.

    Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:23432351.

    • Search Google Scholar
    • Export Citation
  • 238.

    Benson AB III, Hamilton SR. Path toward prognostication and prediction: an evolving matrix. J Clin Oncol 2011;29:45994601.

  • 239.

    O'Connell MJ, Lavery I, Yothers G. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:39373944.

    • Search Google Scholar
    • Export Citation
  • 240.

    Gray RG, Quirke P, Handley K. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011;29:46114619.

    • Search Google Scholar
    • Export Citation
  • 241.

    Venook AP, Niedzwiecki D, Lopatin M. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol 2013;31:17751781.

    • Search Google Scholar
    • Export Citation
  • 242.

    Yothers G, O'Connell MJ, Lee M. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol 2013;31:45124519.

    • Search Google Scholar
    • Export Citation
  • 243.

    Reimers MS, Kuppen PJ, Lee M. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst 2014;106:pii: dju269.

    • Search Google Scholar
    • Export Citation
  • 244.

    Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:15881596.

    • Search Google Scholar
    • Export Citation
  • 245.

    Jager E, Heike M, Bernhard H. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 246.

    O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63:10261030.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 13574 9609 819
PDF Downloads 3894 2797 280
EPUB Downloads 0 0 0